{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:54:57Z","timestamp":1790268897569,"version":"4.1.0"},"reference-count":26,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T00:00:00Z","timestamp":1500422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Chronic spontaneous\/idiopathic urticaria (<jats:styled-content style=\"fixed-case\">CSU<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">CIU<\/jats:styled-content>) has substantial detrimental effects on health\u2010related quality of life (<jats:styled-content style=\"fixed-case\">HRQ<\/jats:styled-content>oL) with an effect comparable to or worse than many other skin diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the effect of omalizumab on <jats:styled-content style=\"fixed-case\">CSU<\/jats:styled-content> patients' <jats:styled-content style=\"fixed-case\">HRQ<\/jats:styled-content>oL, measured by the Dermatology Life Quality Index (<jats:styled-content style=\"fixed-case\">DLQI<\/jats:styled-content>) in three phase <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content> studies <jats:styled-content style=\"fixed-case\">ASTERIA<\/jats:styled-content> I, <jats:styled-content style=\"fixed-case\">ASTERIA II<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">GLACIAL<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A post hoc analysis examined changes in <jats:styled-content style=\"fixed-case\">DLQI<\/jats:styled-content> scores, distribution of patients across <jats:styled-content style=\"fixed-case\">DLQI<\/jats:styled-content> bands and the proportion reaching minimal clinically important difference (<jats:styled-content style=\"fixed-case\">MCID<\/jats:styled-content>) following omalizumab vs. placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Omalizumab 300 mg significantly improved total <jats:styled-content style=\"fixed-case\">DLQI<\/jats:styled-content> scores vs. placebo, with a mean decrease from baseline to week 12 of \u221210.3 vs. \u22126.1 (<jats:italic>P<\/jats:italic> &lt; 0.0001) in <jats:styled-content style=\"fixed-case\">ASTERIA<\/jats:styled-content> I, \u221210.2 vs. \u22126.1 (<jats:italic>P<\/jats:italic> = 0.0004) in <jats:styled-content style=\"fixed-case\">ASTERIA II<\/jats:styled-content> and \u22129.7 vs. \u22125.1 (<jats:italic>P<\/jats:italic> &lt; 0.0001) in <jats:styled-content style=\"fixed-case\">GLACIAL<\/jats:styled-content>. A significant shift from high disease impact on life at baseline towards less impact at week 12 was seen with omalizumab 300 mg vs. placebo (<jats:italic>P<\/jats:italic> &lt; 0.001; all studies). The proportion of patients where change in mean total <jats:styled-content style=\"fixed-case\">DLQI<\/jats:styled-content> score from baseline to week 12 reached an <jats:styled-content style=\"fixed-case\">MCID<\/jats:styled-content> of \u22654 was 74.1%, 76.0% and 77.2% in <jats:styled-content style=\"fixed-case\">ASTERIA<\/jats:styled-content> I, <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">GLACIAL<\/jats:styled-content>, respectively (<jats:italic>P<\/jats:italic> &lt; 0.01; all studies).<\/jats:p><\/jats:sec><jats:sec><jats:title>Limitations<\/jats:title><jats:p>Maximum duration of omalizumab treatment was 24 weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This additional analysis assessed the impact of <jats:styled-content style=\"fixed-case\">CSU<\/jats:styled-content> and benefit of treatment with omalizumab by exploring different facets of <jats:styled-content style=\"fixed-case\">DLQI<\/jats:styled-content> data by treatment arm at multiple assessment points. The original aspects of analysis included applying the concept of the recently validated score for the <jats:styled-content style=\"fixed-case\">MCID<\/jats:styled-content> of the <jats:styled-content style=\"fixed-case\">DLQI<\/jats:styled-content>, changes in <jats:styled-content style=\"fixed-case\">DLQI<\/jats:styled-content> domain scores and in the distribution of subjects based on validated total <jats:styled-content style=\"fixed-case\">DLQI<\/jats:styled-content> score bands. It showed consistently that omalizumab provides significant and clinically relevant improvements in many aspects of <jats:styled-content style=\"fixed-case\">HRQ<\/jats:styled-content>oL that are important to patients with <jats:styled-content style=\"fixed-case\">CSU<\/jats:styled-content>. These results contribute to a better understanding of the impact of <jats:styled-content style=\"fixed-case\">CSU<\/jats:styled-content> and its treatment on patients and can support clinical decision\u2010making in routine medical practice.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.14384","type":"journal-article","created":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T08:36:40Z","timestamp":1496392600000},"page":"1715-1721","source":"Crossref","is-referenced-by-count":50,"title":["Omalizumab substantially improves dermatology\u2010related quality of life in patients with chronic spontaneous urticaria"],"prefix":"10.1111","volume":"31","author":[{"given":"A.Y.","family":"Finlay","sequence":"first","affiliation":[{"name":"Department of Dermatology and Wound Healing Cardiff University School of Medicine Cardiff University Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.P.","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Medical University of South Carolina Charleston SC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.A.","family":"Beck","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of Rochester Medical Center Rochester NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.N.","family":"Antonova","sequence":"additional","affiliation":[{"name":"Genentech, Inc. South San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.\u2010M.","family":"Balp","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Zazzali","sequence":"additional","affiliation":[{"name":"Genentech, Inc. South San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Khalil","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Maurer","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,7,19]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2010.02496.x"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12313"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199506293322608"},{"key":"e_1_2_6_5_1","first-page":"80","article-title":"Assessment of severity and quality of life in chronic urticaria","volume":"24","author":"Jauregui I","year":"2014","journal-title":"J Investig Allergol Clin Immunol"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2009.21.3.226"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2013.09.011"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1997.d01-1168.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06976.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2014.35.3713"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)60928-3"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06385.x"},{"key":"e_1_2_6_13_1","first-page":"577","article-title":"Quality of life in chronic urticaria: a survey at a public university outpatient clinic, Botucatu (Brazil)","volume":"57","author":"Silvares MR","year":"2011","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"e_1_2_6_14_1","unstructured":"Xolair.Summary of product characterisitics.Novartis Europharm Limited Camberley UK 2014."},{"key":"e_1_2_6_15_1","unstructured":"Xolair.Prescribing information.Genentech USA Inc. San Francisco CAand Novartis Pharmaceuticals Corporation East Hanover NJ 2016."},{"key":"e_1_2_6_16_1","unstructured":"Dermatology Life Quality Index (DLQI): Cardiff University; 1992. URLhttp:\/\/sites.cardiff.ac.uk\/dermatology\/quality-of-life\/dermatology-quality-of-life-index-dlqi\/[last accessed 30 January 2015]."},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08832.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1087-0024.2004.09113.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.306"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215372"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.05.013"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23621.x"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1159\/000365390"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-3-36"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1179\/jmt.2008.16.4.82E"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0282-0"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.14384","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.14384","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T14:43:30Z","timestamp":1694961810000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.14384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,19]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1111\/jdv.14384"],"URL":"https:\/\/doi.org\/10.1111\/jdv.14384","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,19]]}}}